Data as of Nov 4, 2026.
BIOY vs NUKX: Dividend Yield & Total Return
BIOY and NUKX both write options for income.
askIQ about this page
askIQ about BIOY and NUKX
Net assets: $1.5m on Nov 3, 2026 for GraniteShares YieldBOOST Biotech ETF, and $7.8m on Jul 31, 2026 for Nicholas Nuclear Income ETF.
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
13.6 pts behind XBI
Total return, distributions reinvested
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
13.6 pts behind XBI
26.1% of it arrived as cash. Total return, distributions reinvested. BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.Not measured
NUKX since launch: paid 7.3%, price −43.5%, total −38.3%, not measured against a benchmark. Data to Nov 4, 2026.
NUKX
−38.3%
Total return, distributions reinvested
Not measured
NUKX since launch: paid 7.3%, price −43.5%, total −38.3%, not measured against a benchmark. Data to Nov 4, 2026.
NUKX
−38.3%
7.3% of it arrived as cash. Both charts share one scale, with zero at the line. NUKX since launch: paid 7.3%, price −43.5%, total −38.3%, not measured against a benchmark. Data to Nov 4, 2026.
Data to Nov 4, 2026.Pair scorecard
NUKX costs 0.11 points a year less.
Points (pts) are percentage points.
| Measure | BIOY | NUKX |
|---|---|---|
| Paid and earned | ||
| Price change | fell 21.9% (since May 5, 2026) | fell 46.6% (6 months) |
| Return of capital, issuer estimate | 96% of the Sep 22, 2026 payment | 100% of the Oct 28, 2026 payment |
| Against its benchmark | ||
| Benchmark | Biotech, measured through XBI | its own holdings |
| Against its benchmark, same days | behind by 13.6 pts | behind by 4.4 pts |
| Cost and size | ||
| Expense ratio | 1.18% | 1.07% |
| Net assets, BIOY as of Nov 3, 2026 and NUKX as of Jul 31, 2026 | $1.5m | $7.8m |
| Holdings | ||
| Holdings in common | 0% | |
What they share
By the books each fund has filed, BIOY and NUKX hold 0% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Jul 31, 2026.
half
0% in common
Only in one fund ↓
Side by side
As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.
Window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | BIOY | NUKX | BIOY | NUKX | BIOY | NUKX |
| 3 months | +6.9% | −23.6% | 14.5% | 2.8% | +2.9 pts | −1.7 pts |
| 6 months | +4.4% | −43.2% | 25.9% | 4.4% | −11.3 pts | −4.4 pts |
| Since launchNot the same days: BIOY May 2026 · NUKX Mar 2026 | +5.4% | −38.3% | 26.1% | 7.3% | −13.7 pts | not measured |
BIOY
Over the period from its first trade on May 5, 2026 to Nov 4, 2026, BIOY paid 26.1% of its starting value in cash distributions while its price fell 21.9%. With every distribution reinvested, the fund returned +5.4%. Biotech (XBI) returned +19.0% over the same days, so a holder was behind by 13.6 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 60.7%, paid weekly. GraniteShares estimates that 96% of the distribution paid Sep 22, 2026 was a return of capital (its 19a-1 notice). That is a tax label, not a measure of erosion.
NUKX's own holdings, without the options (from its filed holdings, rebalanced at each filing; latest Jul 31, 2026) returned −38.8% over the same days, so a holder was behind by 4.4 pts.
Over the 6 months to Nov 4, 2026, NUKX paid 4.4% of its starting value in cash distributions while its price fell 46.6%. With every distribution reinvested, the fund returned −43.2%. At its price on Nov 4, 2026 the latest distribution annualizes to 13.1%, paid weekly. Nicholas estimates that 100% of the distribution paid Oct 28, 2026 was a return of capital (its 19a-1 notice).
Questions people ask
Links are sources, not endorsements. A comparison is not a recommendation.
How this is computed
Overlap adds up the smaller of the two weights for each security both funds hold.
Every number is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, BIOY against NUKX, data as of Nov 4, 2026. https://etfiq.com/compare/income/bioy-vs-nukx
ETFIQ. (Nov 4, 2026). BIOY against NUKX. Retrieved from https://etfiq.com/compare/income/bioy-vs-nukx
[BIOY against NUKX (ETFIQ, Nov 4, 2026)](https://etfiq.com/compare/income/bioy-vs-nukx)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.